Summary: <br> <a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.talkingbiotechpodcast.com%2F945-2%2F&via=talkingbiotech" class="twitter-share-button" data-size="large">Tweet</a><br> <a href="https://i1.wp.com/www.talkingbiotechpodcast.com/wp-content/uploads/2017/11/110-mullin-cover.jpg"></a><br> The promises of gene therapy have been slow to reach the public for many reasons. Technologies conceived in the 1980’s had a substantial regulatory and proof-of-concept road ahead of them, leading to slow development and deployment. One of the major issues is that these therapies were designed for humans, where ethics concerns and regulation are a challenge to navigate. However, it is possible to demonstrate efficacy in animals. Emily Mullin is the Associate Editor at MIT Technology Review. She recently covered the application of gene therapy to animals, and now describes its application in veterinary capacities where regulation is much lower than in human therapy.<br> Follow Emily on Twitter: @emilylmullin<br> Read her work at MIT <a href="https://www.technologyreview.com/">Technology Review</a><br> Like the podcast? Please subscribe and write a review!<br> <a href="http://www.stitcher.com/s?fid=68340&refid=stpr"> Stitche</a>r <a href="https://itunes.apple.com/us/podcast/talking-biotech-podcast/id1006329802">iTunes</a> <a href="https://player.fm/series/talking-biotech-podcast">Player FM</a> <a href="https://poddirectory.com/talkingbiotech">Pod Directory</a> <a href="http://tunein.com/radio/Talking-Biotech-Podcast-p794716/">TuneIn</a><br>
